A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)
|
|
- Willa Mosley
- 5 years ago
- Views:
Transcription
1 A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP) Delivette Castor, PhD USAID Jason Reed, MD, MPH Jhpiego Timothy Mah, DSc USAID Global Health Mini-University September 14, 2017
2 Presentation Overview Oral PrEP Basics What is it? How does it prevent HIV? Who might benefit from Oral PrEP? PrEP Policy and Guidance PrEP introduction and scaleup in SSA What s next? 2
3 What is oral PrEP? A pill taken daily by HIV-negative individuals to reduce their risk of HIV Contains anti-hiv medicine(s) that have been widely used to treat HIV infection Comprised of Tenofovir (TDF) alone or in combination with Emtricitabine (FTC) or Lamivudine (3TC) Brand name (non-generic name) of TDF/FTC combination is Truvada
4 How does oral PrEP prevent HIV? When HIV-negative people take oral PrEP, concentration of anti-hiv medicine(s) gradually builds in their bodies (if they take as prescribed) Should they subsequently be exposed to HIV, the medicine prevents the virus from infecting their body s cells This is similar to the way in which oral contraceptives work to prevent pregnancy and malaria prophylaxis works to prevent malaria
5 How does oral PrEP prevent HIV? HIV Transmitted
6 How does oral PrEP prevent HIV? HIV Not Transmitted
7 What is the evidence that oral PrEP works? Scientific data from a large number of clinical trials and demonstration projects have proven that PrEP is effective at preventing HIV infection On-demand Truvada MSM- France (IPERGA Y) Daily Truvada MSM- UK (PROUD ) Daily Truvada Discordant Couples- Uganda, Kenya (Partners PrEP) Daily Tenofov ir Discordant Couples- Uganda, Kenya (Partners PrEP) Daily Truvada Heterosexu al M & F- Botswana (TDF2) Daily Truvada MSM- America s, Thailand, South Africa (iprex) Daily Truvada Women- Kenya, South Africa, Tanzania (FEMPr EP) Daily Truvada Women- South Africa, Uganda, Zimbabwe (MTN003/ VOICE) Daily Viread Women- South Africa, Uganda, Zimbabwe (MTN003/ VOICE)
8 Consistent protective effect across 5 studies 4 of the 5 studies show >80% protection Evidence in men is compelling (MSM > discordant couples > general heterosexual men) 9/22/2017 8
9 Oral PrEP inconsistent effectiveness across 4 studies Topical PrEP inconsistent effectiveness across 3 studies Effectiveness consistent in those with detectable drug levels 9/22/2017 FOOTER GOES HERE 9
10 PrEP is Over 90% Effective Results indicated that oral PrEP when taken as prescribed over 90% effective at protecting HIV-negative people against HIV In the FTC TDF group, among subjects with a detectable study-drug level, as compared with those without a detectable level, the odds of HIV infection were lower by a factor of 12.9 (95% CI, 1.7 to 99.3; P<0.001), corresponding to a relative reduction in HIV risk of 92% (95% CI, 40 to 99; P<0.001). After adjustment for reported unprotected receptive anal intercourse, the relative risk reduction was 95% (95% CI, 70 to 99; P<0.001). Citation: Grant, Robert M., et al. "Preexposure chemoprophylaxis for HIV prevention in men who have sex with men." New England Journal of Medicine (2010):
11 PrEP Guidance 11
12 WHO Guidance & Support In response to the evidence, WHO issued series of guidance documents, culminating in their 2016 recommendation: oral PrEP be made available to anyone at substantial risk of becoming infected with HIV Added Oral PrEP to the WHO Essential Medicines List in 2017 Released the WHO Oral PrEP Implementation Tool in July
13 PrEP Trajectory in PEPFAR PEPFAR SAB recommends PrEP implementation Pre USAID supported Partner s PrEP OLE, Partner s Demo, FEM-PrEP & several demonstration studies COP Guidance encouraged stakeholder coordination and PrEP readiness activities. - Drug procured w/ non-pepfar funds - DREAMS sites can initiate PrEP - PrEP interagency TF formed Guidance allows for procurement of PrEP ARVs when Test & START policy initiated VL testing in place multi-month scripting for stable ART clients COP guidance Forthcoming 13
14 PEPFAR FY18 PrEP Targets ,000 1,300 1,550 1,680 1,700 1,700 2,769 4,496 11,757 12,815 16,150 23,993 Oct Sept 2018 Total = 82, 096 UNAIDS 2020: 3 Million 14
15 Country Progress on Oral PrEP South Africa PrEP rollout at Sex Worker sites (Mar 2016) Kenya National Oral PrEP Rollout (May 2017) Namibia PrEP Guidelines (WAD 2016) 15
16 PrEP Introduction and Scale-up 16
17 Who might benefit from PrEP? High and medium incidence comprise 95% of HIV infections 17
18 Who might benefit from PrEP? 18
19 Cost and Impact of Potential Roll Out Scenarios 19
20 Framework for Scaling up PrEP OPTIONS project: 20
21 Countries with Demonstration Projects 21
22 CAPRISA 084: PrEP Demonstration Project Objectives: To assess the feasibility, acceptability, uptake and patterns of use of daily, oral tenofovir diproxyl fumarate + emtricitabine provided as part of SRH services to young women (and men) at risk of acquiring HIV in urban and rural KwaZulu-Natal Determine contraceptive use patterns; STIs and pregnancy rates among female PrEP clients Develop a critical mass of trained health care workers skilled to provide PrEP and integrate HIV services into SRH services Characterize PrEP seekers and succesful users Monitor safety of PrEP use in routine services Describe patterns of PrEP use including adherence Determine factors that influence use patterns and adherence What client and provider support is needed for PrEP use? 5
23 CAPRISA 084: Study Sites & Population Enroll clients on oral PrEP Total RURAL Vulindlela n=1200 ANC + FP Clinics + School SRH services URBAN ethekwini n=500 STI clinic + FP clinic + Tertiary institutions PERI-URBAN Umlazi n=300 Pregnant + postpartum Men Age (years) (Range) # enrolled & offered PrEP # (%) initiating PrEP 23.3 (18-30) (61%) # Still on PrEP after 6 months 166 (64%) # Still on PrEP after 12 months As of July (52%) 6
24 CAPRISA 084: Reasons for non-use of PrEP Reasons for not initiating PrEP Not interested / willing / ready to take PrEP HIV test positive, abnormal ALT/AST, medical condition No self-perceived HIV risk Concerned about objection from partner Reasons for stopping PrEP Bad allergic reaction/ rash and swelling of the upper body, Not willing to take ARV medication, Unavailable because of work, No money for transport to get to the clinic, or No longer interested due to lower HIV risk perception
25 Bridge to Scale: Program Overview
26 Overall Project Goal To demonstrate and document an effective model for how oral Pre-exposure Prophylaxis (PrEP) can be scaled up as an HIV-prevention intervention in low-resource settings
27 Priority Population for PrEP Female sex workers (FSWs) Men who have sex with other men (MSM), including male sex workers Adolescent girls and young women (AGYW)
28 Geographic Locations
29 Kenya s PrEP Scale-up Milestones
30 Key Bridge to Scale Milestones
31 Sub Goal 1: Demonstrate Effectiveness of Population Level PrEP Interventions Supply Integrate PrEP into existing combination prevention services Demand Human Centered Design Behavioral Economics
32 Bridge to Scale Service Delivery Points Bridge to Scale Service Delivery Points PrEP is delivered using facility-based and community-based models Drop in Centers - 18 Public Health Facilities - 26 Private Health Facilities - 7 Outreach 32
33 Demand Creation Framework
34 National PrEP Campaign Identity
35 Sub Goal 2: Develop and document an acceptable, affordable, and replicable approach to launch and scale-up the use of oral PrEP Learning laboratory Costing, impact, and affordability (Modeled) Replicability Implementation toolkit
36 Sub Goal 3: Country level & International advocacy Implementation guidelines Domestic and international financing Systems to enable scale up Ensure political, donor, and community support for the scale-up of oral PrEP
37 Media Engagement
38
39 Planned Activities Service Delivery Capacity building of health providers Provision of job aids for providers Commodity quantification based on actual consumption Strengthen supply chain and commodity reporting
40 Demand Creation Less Mass Media and increased Interpersonal Communication
41 Crisis Communications Risk mapping Political, cultural, religious resistance Anti-PrEP activism Risk compensation leading to infection Crisis committee formed Interim crisis strategy in place
42 What is next? 42
43 Different Strokes for Different Folks Method Contraception HIV Prevention Behaviour Barrier Methods Gels not registered Rings with regulatory body Oral pill Injectables? 1 ARV, 1 bnab, 2 vax in/near phase 3; others in pre. Implants? multiple in preclinical Surgical procedures Treatment Prevention Paradigm 2017 and Beyond Source: AVAC.org
44 USAID Microbicide Product Introduction Initiative (MPii) Product R&D Antibodies Long Acting Injectables Films Rings Pre-Clinical T1 - Translation to Human (Move a molecule into product ) T2 - Translation to Patients/Practice (Generate the real world evidence) T3 - Translation to Program (Introduce in existing health systems and scale-up) Minimize delays in introducing HIV/AIDS prevention Better prepare national health systems to deliver new HIV prevention products to Women 9/22/
45
46 THANK YOU! Delivette Castor Jason Reed Timothy Mah 46
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory
More informationUnderstanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationImplementation of PrEP in Kenya
Implementation of PrEP in Kenya National AIDs & STI Control Program Ministry of Health November 2017 HIV in Kenya Context Kenya has the world s fourth largest HIV burden, 1.5 million people living with
More informationOverview and Status of PrEP in Kenya
Overview and Status of PrEP in Kenya Elizabeth Irungu, MBChB, MPH Country Director, Partners Scale Up Project Kenya Stakeholders Meeting on REACH February 8, 2018 Outline National program brief PrEP projects
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationARVs for prevention in at-risk populations: Microbicides
ARVs for prevention in at-risk populations: Microbicides Treatment as Prevention in Africa Meeting Botswana, April 30 May 3, 2014 Salim S Abdool Karim Director: CAPRISA Pro Vice-Chancellor (Research):
More informationInspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5
More informationUpdate on roll out of PrEP
Update on roll out of PrEP Dr Rachel Baggaley, Michelle Rodolph, Dr Shona Dalal, Dr Ioannis Hodges-Mameletzis WHO HIV Department Geneva, Switzerland Regulatory pathways and clinical trial design for long-acting
More informationPre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure
More informationQUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,
More informationThe HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE Overview 1. The Basics 2. A review of the science 3. An update
More informationUpdate on PrEP progress: WHO/UNAIDS challenges and actions
Update on PrEP progress: WHO/UNAIDS challenges and actions Kevin R. O'Reilly Prevention in the Health Sector, HIV/AIDS Department, WHO HQ Outline Review current status of PrEP Planning for PrEP Pre-exposure
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationHP+/Project SOAR Oral PrEP Modeling. Webinar Series: Five Ways to Accelerate Progress Toward the Goals January 16, 2018
HP+/Project SOAR Oral PrEP Modeling Webinar Series: Five Ways to Accelerate Progress Toward the 95-95-95 Goals January 16, 2018 Activity Overview 2 Activity Objective Provide impact, cost, and cost-effectiveness
More informationCombination HIV Prevention Research Carl W. Dieffenbach, Ph.D.
Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationUsing anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
More informationWhat do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women
What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women 6 August 2014, Lilongwe Question #1 HIV testing and safety
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Sharon Hillier, Ph.D. University of Pittsburgh Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine
More informationPlan 4 PrEP: Toolkit for Oral PrEP Implementation STEP 4: READINESS ASSESSMENT
4 Plan 4 PrEP: Toolkit for Oral PrEP Implementation STEP 4: READINESS ASSESSMENT About this toolkit WHAT IS THE PURPOSE AND CONTENTS OF THIS TOOLKIT? This toolkit was developed and used by the OPTIONS
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationOPTIONS REVIEW AND DOCUMENTATION OF M&E INDICATORS FOR ORAL PrEP
OCTOBER 2016 OPTIONS REVIEW AND DOCUMENTATION OF M&E INDICATORS FOR ORAL PrEP Overview of this review Goals of this work Collect Information Summarize current M&E efforts for oral PrEP at the global, country
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking stakeholder perspectives on next steps with the for HIV
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationThe Open Label Trial Past and Present
The Open Label Trial Past and Present Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationWOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society
WOMEN & HIV: A GLOBAL UPDATE Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society Objectives Review the current global burden of HIV among women Trends and progress to date Groups with
More informationThe Open Label Trial Past and Present
The Open Label Trial Past and Present Jared Baeten, M.D., Ph.D. University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention in
More informationPre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:
Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global
More informationPrEP for Women. Together, we can change the course of the HIV epidemic one woman at a time.
PrEP for Women Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is PrEP? PrEP stands for Pre- Exposure Prophylaxis: Prophylaxis: Taking
More informationPrEP efficacy the evidence
PrEP efficacy the evidence Dr Michael Brady Consultant, HIV and Sexual Health King s College Hospital, London Medical Director Terrence Higgins Trust PrEP Pre-exposure prophylaxis Tenofovir and emtricitabine
More informationProgress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa
SUMMARY REPORT Progress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa January December 2012 Table of contents List of acronyms 2 Introduction 3 Summary
More informationTranslating the Science to End New HIV Infections in Kenya
Translating the Science to End New HIV Infections in Kenya Perspectives, Practices and Lessons Nairobi, 28-30 May 2017 www.iasociety.org AIDS 2016 Post-Conference Workshop Setting the Stage Overview of
More informationSuccessful results of clinical trials
Successful results of clinical trials Four clinical trials for HIV prevention in past two years showed different degrees of efficacy > HPTN 052 showed 96% reduction in HIV transmission from HIV infected
More informationVictoria Pilkington, Andrew Hill, Sophie Hughes, Nneka Nwokolo and Anton Pozniak. Pilkington et al. Glasgow HIV Poster 0143
Victoria Pilkington, Andrew Hill, Sophie Hughes, Nneka Nwokolo and Anton Pozniak 36.7 Million 1.8 Million 1 Million NEW INFECTIONS LIVING WITH HIV DEATHS https://www.avert.org/global-hiv-and-aids-statistics.
More informationOn the Horizon for Consideration: Biomedical Advances in HIV Prevention
On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationNovel HIV Prevention Methods for Women
Novel HIV Prevention Methods for Women State of the art injectables, rings, and antibody-mediated prevention Nyaradzo M Mgodi (MBChB, MMed) Principal Investigator University of Zimbabwe- College of Health
More informationPrEP Dosing Strategies
PrEP Dosing Strategies Outline o Background PrEP absorption and tissue penetration o Oral versus topical o Lead in and lead out dosing Time to protection o Cycling on and off PrEP o Balancing toxicity
More informationThe HIV Prevention Pill: The State of PrEP Science and Implementation
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE December 11 th, 2014 Overview 1. The Basics 2. A review of the
More informationSummary of Expected Insights on Oral PrEP for AGYW from Demo Projects in South Africa
March 2017 Summary of Expected Insights on Oral PrEP for AGYW from Demo Projects in South Africa Wits RHI in partnership with FSG and AVAC Work in progress for discussion Introduction A number of questions
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationCombination HIV Prevention
Combination HIV Prevention Timothy Mastro, MD, FACP, DTM&H FHI 360, Durham, North Carolina, USA 7 th INTEREST Workshop, Dakar, Senegal 15 May 2013 Outline What Works for HIV Prevention? Highly Active
More informationPre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection
Pre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection William F. Ryan Community Health Network PrEP Network Coordinator: Trevor Hedberg, MPH, CPH Supervising Health Educator:
More informationDrug development in relation to PrEP and the PROUD study
Drug development in relation to PrEP and the PROUD study David Dolling Medical Statistician MRC Clinical Trials Unit 18 th October 2012 What is PrEP? - Pre-exposure Prophylaxis A strategy that uses antiretrovirals
More informationAbout FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants.
Fact Sheet About FEM-PrEP What is the FEM-PrEP clinical trial? FEM-PrEP is a Phase III randomized, placebo-controlled, clinical trial designed to assess the safety and effectiveness of a daily oral dose
More informationAdolescent PrEP Delivery: Strategies and Tools to Maximize Adherence Young Women in Africa. Jessica Haberer, MD, MS November 9, 2017
Adolescent PrEP Delivery: Strategies and Tools to Maximize Adherence Young Women in Africa Jessica Haberer, MD, MS November 9, 2017 Disclosures I have no conflicts to declare Grant funding: NIH, Gates
More informationOPTIONS. HOPE Protocol Team Meeting Lessons Learned from PrEP Rollout for the Dapivirine Ring. Elizabeth Gardiner, AVAC September 25, 2018
OPTIONS Optimizing Prevention Technology Introduction On Schedule HOPE Protocol Team Meeting Lessons Learned from PrEP Rollout for the Dapivirine Ring Elizabeth Gardiner, AVAC September 25, 2018 Outline
More informationElimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive:
Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive: Rationale for the call to action, progress to date and dealing with realities Rene Ekpini, MD, MPH Senior Adviser,
More informationSupplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations. Age range. Study name and location
Supplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations Study name and location ADAPT (HPTN 067) South Africa, Thailand, US (Harlem) Bangkok Tenofovir
More information8/25/2016. Making Preexposure Prophylaxis Available in the Clinic: Considerations and Pathways Forward
WORKSHOP SESSION: MAKING PREEXPOSURE PROPHYLAXIS AVAILABLE IN THE CLINIC: CONSIDERATIONS AND PATHWAYS FORWARD PRE-REGISTRATION IS REQUIRED PLEASE SEE THE CPT INFORMATION DESK IF THIS IS NOT YOUR SELECTED
More informationAntiretrovirals for HIV prevention:
Antiretrovirals for HIV prevention: Topical PrEP, Systemic PrEP and Treatment for Prevention Presentation at 6th International workshop on HIV treatment, pathogenesis and prevention research in resource-limited
More informationHIV / AIDS. Prevention In Our Lives
HIV / AIDS Prevention In Our Lives Prevention In Our Lives: Produced by the Treatment Action Campaign. Authors: Published: September 2010 Conte n t s Introduction: Statistics on HIV in South Africa 2 Why
More informationThe Evidence Base for Women
The Evidence Base for Women Dr. Busisiwe Msimanga-Radebe WHO South Africa country office ICASA 2017 Abidjan, Cote d Ivoire Combination prevention to break the cycle of HIV transmission Men
More informationInternational Partnership for Microbicides
International Partnership for Microbicides New Directions in Microbicide Research Accelerating an HIV Prevention Revolution: A Roadmap Zeda F. Rosenberg, ScD, Chief Executive Officer Washington, DC, March
More informationLessons from MSM PrEP pilots / demonstration projects. Kevin Rebe
Lessons from MSM PrEP pilots / demonstration projects Kevin Rebe rebe@anovahealth.co.za PrEP Demonstration Projects US: Multisite demonstration project in San Francisco, Miami and Washington DC. South
More informationPRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program
PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program Disclosures None Objectives Review the evidence regarding the
More informationTransmission Networks & Risk of HIV Infection in Young Women in KwaZulu-Natal, South Africa
Transmission Networks & Risk of HIV Infection in Young Women in KwaZulu-Natal, South Africa FIDSSA, Cape Town, November 2017 Quarraisha Abdool Karim, PhD Associate Scientific Director: CAPRISA Professor
More informationINTRODUCTION TIMELINE: PrEP IMPLEMENTATION SA POLICY & GUIDELINES FACILITY AUDIT TOOL IEC MATERIALS MONITORING & EVALUATION
INTRODUCTION TIMELINE: PrEP IMPLEMENTATION SA POLICY & GUIDELINES WHO guidelines [EXECUTIVE SUMMARY] NDoH PrEP policy [FULL] NDoH PrEP guidelines [FULL] FACILITY AUDIT TOOL IEC MATERIALS MONITORING & EVALUATION
More informationPROVIDERS VIEWS ON PREP FOR ADOLESCENT GIRLS AND YOUNG WOMEN IN TANZANIA
results brief 2 PROVIDERS VIEWS ON PREP FOR ADOLESCENT GIRLS AND YOUNG WOMEN IN TANZANIA FINDINGS FROM IMPLEMENTATION SCIENCE RESEARCH JUNE 2017 girls and young women (AGYW) continue to have high rates
More informationPrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
More informationHIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017
HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland An update for registered practitioners September 2017 Key Messages HIV is a major public health challenge for Scotland with an annual average of 359
More informationPrevention targets & scorecard
Prevention targets & scorecard Context Three opportunities For the first time: Global programmatic targets (UN Political Declaration 2016) Translate into pragmatic country road map targets Country and
More informationPEP and PrEP: AWAAC 2014
Acknowledgements: HIVCS PEP guidelines group, Helen Rees, Slim Abdool Karim, Quarraisha Abdool Karim, Clinical Care Options, Edwina Wright, Jared Baeton, AETC PEP and PrEP: AWAAC 2014 Francois Venter Wits
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationPlan 4 PrEP: Toolkit for Oral PrEP Implementation STEP 3: ROLLOUT SCENARIOS
3 Plan 4 PrEP: Toolkit for Oral PrEP Implementation STEP 3: ROLLOUT SCENARIOS About this toolkit WHAT IS THE PURPOSE AND CONTENTS OF THIS TOOLKIT? This toolkit was developed and used by the OPTIONS Consortium
More informationPromoting FP/RH-HIV/AIDS Integration: A Summary of Global Health Initiative Strategies in Ethiopia, Kenya, Tanzania, and Zambia
Promoting FP/RH-HIV/AIDS Integration: A Summary of Global Health Initiative Strategies in Ethiopia, Kenya, Tanzania, and Zambia The Global Health Initiative (GHI) is an integrated approach to global health
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationDREAMS PROJECT. Zandile Mthembu. Programme Manager AWACC October 2016
DREAMS PROJECT Zandile Mthembu Programme Manager AWACC 2016 06 October 2016 Presentation outline Background and Objectives Implementation Approach Interventions/Tools Progress Conclusion QUIZ QUESTION
More informationUnderstanding the Impact of an HIV Intervention Package for Adolescents
Understanding the Impact of an HIV Intervention Package for Adolescents Faikah Bruce Supervisors: Dr. Leigh Johnson (UCT - CIDER) and Prof. Alex Welte (SU - SACEMA) 1 Contents Introduction Literature Review
More informationSUMMARY MEETING REPORT. Annual stakeholders and partners meeting AIDS Medicines and Diagnostics Service. Geneva, 7 8 May 2013
SUMMARY MEETING REPORT Annual stakeholders and partners meeting AIDS Medicines and Diagnostics Service Geneva, 7 8 May 2013 Department of HIV/AIDS HIV Technologies and Commodities May 2013 WHO/HIV/2013.6
More informationUsing PrEP as Harm Reduction. Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination
Be PrEPared! Using PrEP as Harm Reduction Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination Ricky Hill, MA, PhD candidate Team Lead, Community Partnerships and Engagement
More informationDREAMS. Heather Watts M.D. Senior Technical Advisor Office of the US Global AIDS Coordinator US Department of State
DREAMS Heather Watts M.D. Senior Technical Advisor Office of the US Global AIDS Coordinator US Department of State Key Populations Vary by Location Young women are the major key population in Sub-Saharan
More informationInvesting for Impact Prioritizing HIV Programs for GF Concept Notes. Lisa Nelson, WHO Iris Semini, UNAIDS
Investing for Impact Prioritizing HIV Programs for GF Concept Notes Lisa Nelson, WHO Iris Semini, UNAIDS Top 5 Lessons Learned 1 2 3 4 5 Prioritize within the allocation amount Separate above allocation
More informationPEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital
PEP and PREP Dr David Hawkins Chelsea and Westminster Hospital Opportunities for biomedical interventions YEARS HOURS 72 HOURS YEARS Prior to exposure Exposure (pre-coital/ coital) Exposure (pre-coital/
More informationSummary of PEPFAR State of Program Area (SOPA): Care & Support
Summary of PEPFAR State of Program Area (SOPA): Care & Support Prepared by E. Michael Reyes, MD, MPH (Original SOPA is a 45 page document) Introduction: Care and Support refers to the broad array of non-art
More informationOverview November 2017
Pre-Exposure Prophylaxis Implementation in South Africa Overview November 2017 PrEP & T&T Implementation Process 2015 2017 Consultation Policy Implementation October 2015 (Pre- policy) 1 st Draft December
More informationMTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012
MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled
More informationLOGFRAME TEMPLATE FOR SWAZILAND. SIDA s Contributions
1 Outcome 7 countries have addressed barriers to efficient and effective linkages between HIV and SRHR policies and services as part of strengthening health systems to increase access to and use of a broad
More informationOverview of ARV-based prevention trials
Overview of ARV-based prevention trials Catherine Hankins BA MD MSc CCFP FRCPC Deputy Director, Science Amsterdam Institute for Global Health and Development; Department of Global Health, Academic Medical
More informationReview of planned trials and key emerging issues for Thailand
Review of planned trials and key emerging issues for Thailand Frits van Griensven, PhD, MPH Silom Community Clinic Thailand MOPH US CDC Collaboration US Centers for Disease Control and Prevention ilom
More informationOPTIONS Country Situation Analysis Interim Findings: Kenya
FEBRUARY 2017 OPTIONS Country Situation Analysis Interim Findings: Kenya FSG in partnership with LVCT Health OPTIONS Introduction KENYA One of five cooperative agreements awarded by USAID with PEPFAR funding
More informationPre-Exposure Topical Microbicides and Oral Prophylaxis Trials:
Pre-Exposure Topical Microbicides and Oral Prophylaxis Trials: Rationale, Designs & Issues Connie Celum, MD, MPH Patrick Ndase, MBChB, MPH May 2007 Regional MTN Meeting Importance of HIV prevention Antiretroviral
More informationCombination prevention: Public health and human rights imperatives
Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination
More informationProjected Demand for HIV Diagnostic Tests
Projected Demand for HIV Diagnostic Tests John Stover, Yu Teng, Adebiyi Adesina, Eline Korenromp On behalf of the Diagnostics Forecasting Technical Working Group (CDC, CHAI, GFATM, PfSCM, UNAIDS, UNICEF,
More informationBiomedical Prevention in HIV
Biomedical Prevention in HIV CHART - CCAS-CDC 3 RD Joint Meeting Montego Bay, Jamaica August 21-26,2011 Presented by Tina Hylton-Kong, ERTU-CHART Some Slides from Impact of ART on HIV Transmission Wafaa
More informationBiomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013
Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013 Community Education Team The AIDS Institute/AIDS Alliance Be the Generation to End the AIDS Epidemic bethegeneration.nih.gov www.aids-alliance.org/education/vaccine
More informationUpdate on Antiretroviral-Based HIV Prevention
Update on Antiretroviral-Based HIV Prevention Prof. Janneke van de Wijgert University of Liverpool, Institute of Infection and Global Health Click to edit Master subtitle style 12th European Meeting on
More informationElements of Reproductive Health
SEXUAL& REPRODUCTIVE HEALTH and HIV/AIDS INTEGRATION: Issues for consideration Dr. Chris Baryomunsi, MP Parliament of Uganda Elements of Reproductive Health Safe motherhood Family Planning Prevention and
More informationGetting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day
Getting Prepped for PrEP Ken Ho, MD, MPH World AIDS Day Objectives HIV epidemiology What is PrEP? Does it Work? Who gets PrEP? How do I prescribe PrEP What to do at the first visit? What to do at follow
More informationNairobi City s Progress Towards Ending the HIV Epidemic. Dr. Carol Ngunu-Gituathi Deputy Director, Health Services, NAIROBI
Nairobi City s Progress Towards Ending the HIV Epidemic Dr. Carol Ngunu-Gituathi Deputy Director, Health Services, NAIROBI Presentation Outline Kenya HIV Situation City County Profile Key Achievements
More informationUganda Actions for Acceleration FP2020
Uganda Actions for Acceleration FP2020 Other modern 2.7% Country Snapshot Country Snapshot Modern Contraceptive Method Mix Condoms (m) 13.7% Pills 8.2% Injection 51.8% Sterilization (f) 5.9% IUD 1.2% Sterilization
More informationSteady Ready Go! teady Ready Go. Every day, young people aged years become infected with. Preventing HIV/AIDS in young people
teady Ready Go y Ready Preventing HIV/AIDS in young people Go Steady Ready Go! Evidence from developing countries on what works A summary of the WHO Technical Report Series No 938 Every day, 5 000 young
More informationWhich Scale Up Strategies/Programmatic Mixes are most Cost-Effective? Iris Semini UNAIDS May 2018
Which Scale Up Strategies/Programmatic Mixes are most Cost-Effective? Iris Semini UNAIDS May 2018 Outline Scaling up for Impact Critical Point of the Response Choices of strategies Accelerating Implementation
More informationFHI Study 10015: FEM-PrEP
FHI Study 10015: FEM-PrEP Phase 3, multi-center, double-blind, randomized, placebo-controlled effectiveness and safety study to assess the role of Truvada in preventing HIV acquisition in women MTN Annual
More informationUSG Update on Family Planning/HIV Integration
USG Update on Family Planning/HIV Integration Nithya Mani, USAID/Office of HIV/AIDS Jennifer Mason, USAID/Office of Population and Reproductive Health IAWG SRH and HIV Linkages Meeting March 9-10, 2015
More informationDifferentiated Service Delivery: Taking Innovative Delivery Models to Scale
Differentiated Service Delivery: Taking Innovative Delivery Models to Scale Wafaa El-Sadr, MD, MPH, MPA ICAP at Columbia University Outline The Promise of Differentiated Service Delivery (DSD) Scale-up
More information